Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
13 results loaded, newest first. End of these results.
Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: The Morning News Call newsletter: Oct 13 (Reuters) — Futures tied to the S&P 500 were muted on Tuesday, with major US banks scheduled to report earnings while weakness in chip stocks weighed on Nasdaq futures..N * VF Corp: BUZZ- Piper S
Johnson & Johnson reported third-quarter adjusted earnings of $2.59 per share, above expectations, and raised its full-year outlook. Medical technology business stumbles left investors lukewarm.
(This story was generated using AI and automation, please see disclaimer ) Overview US healthcare conglomerate's Q3 sales rose 5.9%, slightly beating analyst expectations Adjusted EPS for Q3 was $2.59, beating analyst expectations Company raised 2026 sales and adjusted EPS guidance Outlook Johnson & Johnson raises 2026
Johnson & Johnson posted Q3 2026 net earnings of USD 210 million, swinging from profit a year earlier. Reported sales rose 6% to USD 25.4 billion versus Q3 2025. * Innovative Medicine net sales climbed 8% to USD 16.76 billion, while MedTech net sales increased to USD 8.64 billion. CEO Joaquín Duato cited “accelerating
For best results when printing this announcement, please click on link below: Johnson & Johnson reports Q3 2026 results, raises 2026 guidance 2026 Third-Quarter reported sales growth of 5.9% to $25.4 Billion with operational growth of 6.0%* and adjusted operational growth of 6.1% 2026 Third-Quarter earnings per share (
Adj. EPS $2.59, est. $2.52 Revenue $24.60B, est. $24.21B MedTech Sales $8.64B, est. $8.77B Medicine Revenue $16.76B, est. $16.59B Darzalex Revenue $4.24B, est. $4.31B FY Adj. EPS Outlook $11.05—$11.15, prior $10.96—$11.11 FY Adj. Operating EPS Outlook $10.95—$11.05, prior $10.86—$11.01 FY Sales Outlook $101B—$101.4B, p
(Repeats BUZZ published on Monday with no changes) * Johnson & Johnson shares up 0.6% at $263.00 on Mon ahead of qtrly results before the bell, with investors watching for a rebound in its medtech unit * The healthcare conglomerate is expected to post Q3 rev of $25.28 bln and adj EPS of $2.54, down from EPS of $2.80 bu
* Johnson & Johnson shares up 0.6% at $263.00 on Mon ahead of qtrly results before the bell, with investors watching for a rebound in its medtech unit * The healthcare conglomerate is expected to post Q3 rev of $25.28 bln and adj EPS of $2.54, down from EPS of $2.80 but up from revenue of $23.99 bln a year ago, per LSE
Earnings season kicks off this week as several of the largest financial companies report quarterly financial results. The week is a big one for the Dow Jones Industrial Average, with five of its 30 components reporting. Dow Jones Industrial Average Gets Spotlight To kick off earnings season, the Dow Jones Industrial Av
Johnson & Johnson is scheduled to report Q3'26 results on October 13 before the market opens. Revenue is estimated at 25.38 billion USD and EPS at 2.52 USD.
JNJ (Johnson & Johnson) is set to announce its Q3'26 results on October 13, before the market opens. The earnings are expected to be disclosed at 6:45 AM ET (10:45 AM UTC).For Q3'26, revenue estimate is 25.36 billion USD with EPS (earnings per share) anticipated at 2.72 USD. Learn more details at J…
BofA Securities raised its price target on Johnson & Johnson NYSE:JNJ to $278 from $263 while keeping a Neutral rating, lifting its forecasts for Icotyde and updating its model for recent in-process research and development charges. J&J shares were down 0.22% in premarket.The new target applies 22x…
Johnson & Johnson will release Q3 results Oct. 13, with a 6:45 a.m. ET press release and 8:30 a.m. ET earnings call/webcast. UBS raised its price target to $320 from $280.